%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES
%A Ariza-Vioque, E.
%A Ello, F.
%A Andriamamonjisoa, H.
%A Machault, V.
%A Gonzalez-Martin, J.
%A Calvo-Cortes, M. C.
%A Eholie, S.
%A Tchabert, G. A.
%A Ouassa, T.
%A Raberahona, M.
%A Rakotoarivelo, R.
%A Razafindrakoto, H.
%A Rahajamanana, L.
%A Wilkinson, R. J.
%A Davis, A.
%A Maxebengula, M.
%A Abrahams, F.
%A Muzoora, C.
%A Nakigozi, N.
%A Nyehangane, D.
%A Nanjebe, D.
%A Mbega, H.
%A Kaitano, R.
%A Bonnet, Maryline
%A Beaudrap, Pierre de
%A Miro, J. M.
%A Anglaret, X.
%A Rakotosamimanana, N.
%A Calmy, A.
%A Bonnet, F.
%A Ambrosioni, J.
%A INTENSE-TBM Group
%T Capacity building in Sub-Saharan Africa as part of the INTENSE-TBM project during the COVID-19 pandemic [Commentaire]
%D 2022
%L fdi:010085353
%G ENG
%J Infectious Diseases and Therapy
%@ 2193-8229
%K Africa ; Capacity building ; Clinical research ; HIV ; INTENSE-TBM ; Tuberculous meningitis
%K AFRIQUE SUBSAHARIENNE ; COTE D'IVOIRE ; MADAGASCAR ; AFRIQUE DU SUD ; OUGANDA
%M ISI:000818677900001
%N 4
%P 1327-1341
%R 10.1007/s40121-022-00667-z
%U https://www.documentation.ird.fr/hor/fdi:010085353
%> https://horizon.documentation.ird.fr/exl-doc/pleins_textes/2023-02/010085353.pdf
%V 11
%W Horizon (IRD)
%X Tuberculous meningitis (TBM) is the most severe and disabling form of tuberculosis (TB), with at least 100,000 cases per year and a mortality rate of up to 50% in individuals co-infected with human immunodeficiency virus type 1 (HIV-1). To evaluate the efficacy and safety of an intensified anti-tubercular regimen and an anti-inflammatory treatment, the INTENSE-TBM project includes a phase III randomised clinical trial (TBM-RCT) in four countries in sub-Saharan Africa (SSA). Within this framework, we designed a comprehensive capacity-building work package ensuring all centres had, or would acquire, the ability to conduct the TBM-RCT and developing a network of skilled researchers, clinical centres and microbiology laboratories. Here, we describe these activities, identify strengths/challenges and share tools adaptable to other projects, particularly in low- and lower-middle income countries with heterogeneous settings and during the coronavirus disease 2019 (COVID-19) pandemic. Despite major challenges, TBM-RCT initiation was achieved in all sites, promoting enhanced local healthcare systems and encouraging further clinical research in SSA. In terms of certified trainings, the achievement levels were 95% (124/131) for good clinical practice, 91% (39/43) for good clinical laboratory practice and 91% (48/53) for infection prevention and control. Platform-based research, developed as part of capacity-building activities for specific projects, may be a valuable tool in fighting future infectious diseases and in developing high-level research in Africa.
%$ 050 ; 052